Gland Pharma in deal with US drugmaker to market injectables

6 December 2016

Privately-held US generic drug distributor Breckenridge Pharmaceuticals has entered into a multi-product marketing agreement with development and manufacturing partner Gland Pharma of India for seven injectable products.

Under the terms of this agreement, Breckenridge will market and distribute the products under its label in the USA. The deal includes six approved Abbreviated New Drug Applications (ANDAs) and one tentatively-approved ANDA. Financial details were not disclosed.

The products cover a wide range of indications. This deal further showcases Breckenridge's entry into the institutional market and expanding injectable portfolio, the US company says.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK